Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on LTR Pharma.
RELATED STOCKHEAD STORIES
Health & Biotech
The ASX pharmas playing the long game, with commercialisation the prize
Biocurious: Sometimes an effective therapy lies not just with the drug, but how it is delivered
News
Lunch Wrap: ASX slumps on new China tariffs; Star in dire straits
Health & Biotech
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health & Biotech
ASX Quarterly Health Wrap: Bioxyne revenue up 77%, Radiopharm lists on Nasdaq
Health & Biotech
LTR Pharma inks national pharmacy distribution deal for its ED therapy
News
Closing Bell: Iron ore miners hammered, but Trump’s Canada tariffs boost uranium stocks
Health & Biotech
Health Check: We’ll see you in court and you bladder believe it, says Pacific Edge after unfavourable US ruling
Health & Biotech
LTR Pharma inks deal with men’s health provider for ED therapy
Health & Biotech
Health Check: Joy as Mesoblast wins its first FDA approval for a stem-cell therapy after decades of trying
Break It Down
Break it Down: Quick access to quick ED fix from LTR Pharma
Health & Biotech
LTR Pharma successfully completes $25m cap raise to accelerate novel ED treatment
Health & Biotech
Health Check: The robots are taking over biotech stock selection
Health & Biotech
Renerve all set to become only the second nerve-repair stock on the ASX
Health & Biotech
LTR Pharma joins with leading men’s health group to launch telehealth platform
Health & Biotech
Health Check: It’s a small world after all for global microcap index additions LTR Pharma and EZZ Life Science
Health & Biotech
